HBC Immunology LLC , a majority owned subsidiary of Hofseth BioCare ASA , has successfully completed the required minimum seed capital financing of approx. USD 900,000 from external.
HBC is pleased to announce the online publication of its abstract titled “Antiproliferative activity of marine-derived oligopeptides combined with androgen.
HBC is pleased to announce the online publication of its abstract titled “Antiproliferative activity of marine-derived oligopeptides combined with androgen receptor inhibition in preclinical. | May 30, 2023
The study, published in prestigious peer-reviewed journal Biomolecules by MDPI, was conducted through a collaboration between Hofseth BioCare (HBC) and.